Woodline Partners LP Invests $42.25 Million in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Woodline Partners LP acquired a new stake in Alnylam Pharmaceuticals worth approximately $42.25 million, owning about 0.12% of the company after the purchase.
• Several analysts have increased their target prices for Alnylam Pharmaceuticals, with Bank of America raising it to $359 and Oppenheimer setting a target as high as $490.
• Alnylam Pharmaceuticals reported $773.69 million in revenue for the last quarter, exceeding expectations and marking a 17.3% year-over-year increase.

Woodline Partners LP acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 156,464 shares of the biopharmaceutical company's stock, valued at approximately $42,248,000. Woodline Partners LP owned about 0.12% of Alnylam Pharmaceuticals as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. SVB Wealth LLC bought a new position in shares of Alnylam Pharmaceuticals during the 1st quarter valued at about $27,000. Whipplewood Advisors LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 71 shares during the last quarter. Bessemer Group Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 69 shares during the last quarter. Park Square Financial Group LLC bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $28,000. Finally, Washington Trust Advisors Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 53.5% in the 1st quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 61 shares during the last quarter. Institutional investors own 92.97% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Scotiabank increased their price target on shares of Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a "sector outperform" rating in a report on Friday, August 1st. UBS Group increased their price target on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a "buy" rating in a report on Friday, August 1st. Wells Fargo & Company increased their price target on shares of Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the company an "equal weight" rating in a report on Friday, August 1st. Truist Financial assumed coverage on shares of Alnylam Pharmaceuticals in a report on Monday, July 21st. They issued a "buy" rating and a $385.00 price target for the company. Finally, Piper Sandler increased their price target on shares of Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the company an "overweight" rating in a report on Friday, August 1st. Twenty-three analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $421.28.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 6,979 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $453.27, for a total transaction of $3,163,371.33. Following the transaction, the chief executive officer directly owned 56,221 shares of the company's stock, valued at approximately $25,483,292.67. This trade represents a 11.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Jeffrey V. Poulton sold 2,274 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $453.27, for a total transaction of $1,030,735.98. Following the transaction, the executive vice president directly owned 50,121 shares in the company, valued at approximately $22,718,345.67. This trade represents a 4.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 75,594 shares of company stock valued at $33,968,256. 1.50% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Trading Down 0.6%

Alnylam Pharmaceuticals stock traded down $2.69 during midday trading on Friday, reaching $465.89. The stock had a trading volume of 630,774 shares, compared to its average volume of 1,113,410. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $484.21. The firm has a market cap of $61.07 billion, a price-to-earnings ratio of -188.62 and a beta of 0.32. The company has a fifty day moving average of $401.46 and a 200 day moving average of $317.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. During the same period in the prior year, the company posted ($0.13) EPS. The firm's revenue for the quarter was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.